A Study of Ixekizumab in Participants With Plaque Psoriasis
Status:
Completed
Trial end date:
2017-11-21
Target enrollment:
Participant gender:
Summary
This study is known as a "drug interaction study." The purpose is to learn about how
ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine,
omeprazole, warfarin, dextromethorphan, and midazolam) that are metabolized by cytochrome
P450. Each participant will complete two study periods. Participants will take the mixture of
commonly used drugs (plus vitamin K) by mouth on 3 occasions (prior to treatment with
ixekizumab and after 1 and 12 weeks of treatment with ixekizumab). The study will last about
17 weeks, including follow-up. Screening must be completed prior to study start.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Caffeine Dextromethorphan Ixekizumab Midazolam Omeprazole Vitamin K Vitamins Warfarin